File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aspergillosis in bone marrow transplant recipients

TitleAspergillosis in bone marrow transplant recipients
Authors
Issue Date2000
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/critrevonc
Citation
Critical Reviews In Oncology/Hematology, 2000, v. 34 n. 1, p. 55-69 How to Cite?
AbstractInvasive aspergillosis in bone marrow transplant recipient is associated with a high mortality. Diagnosis is often delayed because the inflammatory response is blunted by immunosuppression. The gold standard of tissue biopsy is often considered too in invasive as the procedure is often complicated by bleeding and secondary infection. Recent finding on non-invasive tests such as serial measurement of peripheral blood galactomannan antigen or DNA appears to be promising. However, the limited availability of such tests and requirement for expertise are still hampering their use in routine clinical management. More often than not, initiation of antifungal therapy is empirical and based on suggestive radiological changes. Amphotericin B remains the gold standard of therapy but liposconal preparation may prove to be less nephrotoxic and equally effective. Treatment outcome depends more on the acceleration of the recovery of the immune system and the reduction of anti-GVHD therapy than the antifungal agent followed by surgical resection. The efficacy of many reported anti-aspergillosis prophylactic regimen has not been proved in randomized control trials. Despite the absence of data, such policy should still be considered in transplant units with high incidence of aspergillus or undergoing renovation. (C) 2000 Elsevier Science Ireland Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/79041
ISSN
2015 Impact Factor: 5.039
2015 SCImago Journal Rankings: 1.864
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, PLen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2010-09-06T07:49:52Z-
dc.date.available2010-09-06T07:49:52Z-
dc.date.issued2000en_HK
dc.identifier.citationCritical Reviews In Oncology/Hematology, 2000, v. 34 n. 1, p. 55-69en_HK
dc.identifier.issn1040-8428en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79041-
dc.description.abstractInvasive aspergillosis in bone marrow transplant recipient is associated with a high mortality. Diagnosis is often delayed because the inflammatory response is blunted by immunosuppression. The gold standard of tissue biopsy is often considered too in invasive as the procedure is often complicated by bleeding and secondary infection. Recent finding on non-invasive tests such as serial measurement of peripheral blood galactomannan antigen or DNA appears to be promising. However, the limited availability of such tests and requirement for expertise are still hampering their use in routine clinical management. More often than not, initiation of antifungal therapy is empirical and based on suggestive radiological changes. Amphotericin B remains the gold standard of therapy but liposconal preparation may prove to be less nephrotoxic and equally effective. Treatment outcome depends more on the acceleration of the recovery of the immune system and the reduction of anti-GVHD therapy than the antifungal agent followed by surgical resection. The efficacy of many reported anti-aspergillosis prophylactic regimen has not been proved in randomized control trials. Despite the absence of data, such policy should still be considered in transplant units with high incidence of aspergillus or undergoing renovation. (C) 2000 Elsevier Science Ireland Ltd.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/critrevoncen_HK
dc.relation.ispartofCritical Reviews in Oncology/Hematologyen_HK
dc.rightsCritical Reviews in Oncology / Hematology. Copyright © Elsevier Ireland Ltd.en_HK
dc.subject.meshAir Microbiologyen_HK
dc.subject.meshAntifungal Agents - therapeutic useen_HK
dc.subject.meshAspergillosis - diagnosis - epidemiology - prevention & controlen_HK
dc.subject.meshBone Marrow Transplantation - adverse effectsen_HK
dc.subject.meshDisease Transmission, Infectiousen_HK
dc.subject.meshHumansen_HK
dc.subject.meshPrognosisen_HK
dc.titleAspergillosis in bone marrow transplant recipientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1040-8428&volume=34&spage=55&epage=69&date=2000&atitle=Aspergillosis+in+bone+marrow+transplant+recipients.en_HK
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityHo, PL=rp00406en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S1040-8428(00)00047-0en_HK
dc.identifier.pmid10781748-
dc.identifier.scopuseid_2-s2.0-0034000041en_HK
dc.identifier.hkuros50546en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034000041&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue1en_HK
dc.identifier.spage55en_HK
dc.identifier.epage69en_HK
dc.identifier.isiWOS:000087010800003-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridHo, PL=7402211363en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats